Amgen (NQ:AMGN)

The High-Stakes Balancing Act: Johnson & Johnson Braces for Q4 Earnings Amid Patent Cliffs and MedTech Expansion

January 20, 2026

As the opening bell approaches on January 21, 2026, all eyes on Wall Street are fixed on Johnson & Johnson (NYSE: JNJ), which is set to report its fourth-quarter and full-year 2025 financial results....

They are unlikely to resort to dividend cuts anytime soon.

Topics Bankruptcy Earnings Economy

Why Is ZBIO Stock Falling Pre-Market Today? ↗

January 06, 2026

Via Stocktwits

Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All ↗

January 19, 2026

Via MarketBeat

Topics ETFs

2 Dividend Stocks to Buy and Hold For 10 Years ↗

January 19, 2026

Via The Motley Fool

Topics Intellectual Property

The Trillion-Dollar Pharmacopeia: Eli Lilly’s (LLY) Dominance in the Age of Incretins

January 19, 2026

As of January 19, 2026, the pharmaceutical landscape is being redefined by a single name: Eli Lilly and Company (NYSE: LLY). Once a steady, century-old stalwart known for its dominance in the insulin...

Via Finterra

Topics Economy

Q3 Therapeutics Earnings: Halozyme Therapeutics (NASDAQ:HALO) Earns Top Marks

January 18, 2026

Wrapping up Q3 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Halozyme Therapeutics (NASDAQ:HALO) and its peers.

As the global economy shakes off the final remnants of the high-interest-rate era, a massive wave of consolidation is sweeping through corporate boardrooms. Analysts have officially adjusted their...

Topics Artificial Intelligence

The $5.1 Trillion Wave: Why 2026 is Set to Become the Biggest Year for Global M&A

January 16, 2026

As of January 15, 2026, Merck & Co. (NYSE: MRK) has emerged as the standout performer in the pharmaceutical sector, defying the gravity of looming patent expirations with a series of strategic...

Topics Artificial Intelligence Economy

The Execution Engine: How Merck is Dominating the 2026 Pharma Landscape

January 15, 2026

Date: January 13, 2026 Introduction Amgen Inc. (NASDAQ: AMGN) finds itself at a historic crossroads. Long regarded as the "blue-chip" anchor of the biotechnology sector, the Thousand Oaks-based giant...

Topics Economy Intellectual Property

Amgen at the Crossroads: MariTide, Market Volatility, and the Quest for Obesity Dominance

January 13, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but...

Topics Economy Intellectual Property

1 Healthcare Stock to Keep an Eye On and 2 We Ignore

January 12, 2026

The Convergence of Silicon and Science: Eli Lilly and Nvidia Unveil $1 Billion AI Co-Innovation Lab at JPM26

Topics Stocks

January 12, 2026

In a move that signals the definitive arrival of the "AI-first" era for the pharmaceutical industry, Eli Lilly and Company (NYSE:LLY) and NVIDIA Corporation (NASDAQ:NVDA) announced a massive expansion...

As of January 9, 2026, Eli Lilly and Company (NYSE:LLY) has transitioned from a stalwart of the American pharmaceutical industry to a global financial phenomenon. Having recently crossed the historic...

Topics Artificial Intelligence

The Trillion-Dollar Pharmacist: A 2026 Deep Dive into Eli Lilly (LLY)

January 09, 2026

The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader

Topics Earnings Economy Intellectual Property

J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs ↗

January 08, 2026

Via Stocktwits

Topics Government

January 08, 2026

The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (NASDAQ: RVMD) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood...

There is an even more important question to address.

Topics Intellectual Property

Can These Dividend Stocks Beat the Market Again in 2026? ↗

January 08, 2026

Via The Motley Fool

The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance

January 07, 2026

As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent...

The Trillion-Dollar Pivot: Eli Lilly Unleashes Volume-Led Strategy to Cement Obesity Market Dominance in 2026

Topics Artificial Intelligence Economy Intellectual Property

January 06, 2026

As of January 6, 2026, the landscape of the pharmaceutical industry has been fundamentally reshaped by Eli Lilly and Company (NYSE:LLY), which recently became the first healthcare entity to surpass a...

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural...

Topics Economy

1 S&P 500 Stock with Exciting Potential and 2 We Question

January 04, 2026

The 2026 Pharma Reset: How Industry Giants Are Navigating a New Era of Federal Price Controls

Topics Stocks

January 02, 2026

Yesterday marked the official commencement of the first-ever "Maximum Fair Prices" (MFPs) for ten of the most widely used drugs in the Medicare program, a direct result of the Inflation Reduction Act’s...

As the calendar turns to January 2, 2026, the investment landscape is undergoing a tectonic shift. After years of dominance by mega-cap technology giants, the "Great Rotation" has finally reached the...

Topics Economy Intellectual Property World Trade

The Rise of the 'Dividogs': Small-Cap Yield Kings Poised to Lead the 2026 Market Rotation

January 02, 2026

The GLP-1 Pricing Revolution: How Novo Nordisk and Eli Lilly Redefined the Weight-Loss Market for 2026

Topics Artificial Intelligence Economy Stocks

January 02, 2026

As the calendar turns to 2026, the landscape for weight-loss and diabetes medication has been fundamentally transformed. What began two years ago as a "wild west" of $1,000-a-month list prices and...

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Topics Economy Intellectual Property

1 Safe-and-Steady Stock to Keep an Eye On and 2 We Question

December 30, 2025

Amgen’s 17.6% return over the past six months has outpaced the S&P 500 by 6.3%, and its stock price has climbed to $328.43 per share. This was partly due to its solid quarterly results, and the...

Amgen (AMGN): Buy, Sell, or Hold Post Q3 Earnings?

December 30, 2025

As of late 2025, the global pharmaceutical landscape has undergone a tectonic shift, and at its center stands Eli Lilly and Company (NYSE: LLY). Once regarded as a steady, dividend-paying stalwart of...

Topics Stocks

The Trillion-Dollar Apothecary: Inside Eli Lilly’s Era of Metabolic Dominance

December 29, 2025

Companies with solid operating margins have a competitive edge, allowing them to reinvest for sustainable expansion. The best of these businesses balance profitability with reinvestment, setting...

Topics Earnings Economy Intellectual Property

3 Profitable Stocks with Competitive Advantages

December 28, 2025

As investors close the books on 2025, a year defined by the continued—yet tiring—dominance of artificial intelligence and mega-cap technology, the financial community is turning its gaze toward a...

Barking Back: Why the 'Dogs of the Dow' 4-Stock Play is the Contrarian Bet for 2026

December 25, 2025

Introduction As of December 25, 2025, the global pharmaceutical landscape is witnessing a seismic shift centered on a single Danish company: Novo Nordisk (NYSE: NVO). Long the undisputed king of the...

Topics Artificial Intelligence Economy Intellectual Property

The Oral Revolution: Novo Nordisk’s High-Stakes Bet on the Wegovy Pill

December 25, 2025

The Trillion-Dollar Pharma: A Deep Dive into Eli Lilly’s (LLY) Dominance in the Weight-Loss Era

Topics Economy Intellectual Property World Trade

December 25, 2025

As of December 25, 2025, the global pharmaceutical landscape has been fundamentally reshaped by a single entity: Eli Lilly and Company (NYSE: LLY). In a year defined by breakthrough medical treatments...